<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100316</url>
  </required_header>
  <id_info>
    <org_study_id>213033</org_study_id>
    <nct_id>NCT05100316</nct_id>
  </id_info>
  <brief_title>Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials</brief_title>
  <official_title>A Screening Protocol to Support Preliminary Eligibility for Clinical Trials Evaluating Safety and Efficacy of Adoptive Cell Therapies in Participants With Solid Tumors and Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This screening study is intended to determine preliminary eligibility of participants who may&#xD;
      be potential candidates for GlaxoSmithKline's Adoptive T-cell therapy studies by screening&#xD;
      for appropriate biomarkers. No treatment intervention will occur as part of this screening&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 19, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Human Leukocyte Antigen (HLA) genotypes (HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06)</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Participants with solid tumors and hematological malignancies</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants with solid tumors and hematological malignancies will be included. No study treatment will be administered in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Screening Platform</intervention_name>
    <description>Eligible participants who qualify as per this screening protocol may be referred to evaluate adoptive cell therapy in participants with various malignancies, on a separate treatment trial. No study treatment will be administered in this screening study.</description>
    <arm_group_label>Participants with solid tumors and hematological malignancies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of locally advanced high-risk&#xD;
             eligible tumor types .&#xD;
&#xD;
          -  Participant must be greater than or equal to (&gt;=)18 years of age (or &gt;=10 years of age&#xD;
             with synovial sarcoma or myxoid/round cell liposarcoma [MRCLS])&#xD;
&#xD;
          -  Participants with life expectancy of greater than 6 months&#xD;
&#xD;
          -  Performance status: Eastern Cooperative Oncology Group 0-1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior treatment with oncology cell and/or gene therapy (unless agreed in advance&#xD;
             with Sponsor)&#xD;
&#xD;
          -  Prior malignancy not in complete remission.&#xD;
&#xD;
          -  Clinically significant systemic illness&#xD;
&#xD;
          -  Serious active infections or significant cardiac, pulmonary, hepatic or other organ&#xD;
             dysfunction,&#xD;
&#xD;
          -  Prior or active demyelinating disease&#xD;
&#xD;
          -  Previous New-York Esophageal Antigen-1 (NY-ESO-1)-specific T cells, NY-ESO-1 vaccine,&#xD;
             or NY-ESO-1 targeting antibody.&#xD;
&#xD;
          -  Previous allogeneic hematopoietic stem cell transplant within the last 5 years or&#xD;
             solid organ transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adoptive T-cell therapy</keyword>
  <keyword>Hematologic Malignancy</keyword>
  <keyword>Human leukocyte antigen</keyword>
  <keyword>Screening study</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>T-cell receptors</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

